MINI FUTURE LONG - ZEALAND PHARMA | Market Closed - Börse Stuttgart 12:49:43 2024-06-05 EDT | ||
| 4.44 EUR | -0.22% |
|
| Current month | -8.07% | ||
| 1 month | -3.27% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ZEALAND PHARMA A/S
Latest news about ZEALAND PHARMA A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-05 | 4.44 | -0.22% |
| 24-06-04 | 4.45 | -9.74% |
| 24-06-03 | 4.93 | +2.07% |
| 24-05-31 | 4.83 | +10.78% |
| 24-05-30 | 4.36 | -2.02% |
Delayed Quote Börse Stuttgart
Last update June 05, 2024 at 12:49 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ZEALAND PHARMA A/S |
| Issuer | Morgan Stanley |
| WKN | ME4D4D |
| ISIN | DE000ME4D4D0 |
| Date issued | 2023-11-29 |
| Strike | 277.4 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.75 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.57 € |
|---|---|
| Lowest since issue | 0.71 € |
Company Profile
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Sector
-
Consensus: Zealand Pharma A/S
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
610.5
DKK
Average target price
785.6
DKK
Spread / Average Target
+28.68%
- Stock Market
- Certificates
- Certificat
